NervGen Pharma Corp.

NervGen Pharma Corp. (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. NervGen’s lead drug candidate is NVG-291 and the company’s initial target indication is spinal cord injury.